Emergent BioSolutions authorizes $50M share repurchase program through March 2026

Emergent BioSolutions Inc.

Board authorized repurchase of up to $50 million of common stock on or before March 27, 2026.
CEO Joe Papa cites confidence in strategy, future outlook and cash generation as rationale.
Company had approximately 54.3 million shares outstanding as of December 31, 2024.
Repurchases may be made on open market or in private transactions; timing subject to market conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.